This randomized clinical trial examines the safety and efficacy of oral nalbuphine in patients with chronic cough caused by idiopathic pulmonary fibrosis.
JAMA (Journal of the American Medical Association) published a clinical update in Research Highlights on 24 Mar 2026.
The item focuses on Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough.
Review the original article for the full source wording and details.